Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© 2019 Healthcare systems that provide care free of charge at the point of care must evaluate health interventions for effectiveness and cost-effectiveness. This is as true for treatments for obesity as it is for any disease area, and the same money cannot be spent at the same time on obesity and other disease areas necessitating these evaluations. Cost–utility analyses carried out to inform payers typically ask whether a new health intervention makes people live longer and/or better than the existing standard of care. The costs associated with one versus another intervention, including the costs and benefits of all downstream sequelae, comprise the incremental cost-effectiveness ratio. Uncertainties exist because estimates of life-long treatment rely on the results of short-term clinical studies.

Original publication

DOI

10.1016/j.mpmed.2018.12.001

Type

Journal article

Journal

Medicine (United Kingdom)

Publication Date

01/03/2019

Volume

47

Pages

188 - 189